| 1. |
Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol, 2010, 9(4): 413-424.
|
| 2. |
Noebels JL, Avoli M, Rogawski MA, et al. Jasper's basic mechanisms of the epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US), 2012.
|
| 3. |
Hoy SM. Lacosamide: a review in focal-onset seizures in patients with epilepsy. CNS Drugs, 2018, 32(5): 473-484.
|
| 4. |
Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia, 2007, 48(7): 1308-1137.
|
| 5. |
Halász P, K?lvi?inen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia, 2009, 50(3): 443-453.
|
| 6. |
Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia, 2010, 51(6): 958-967.
|
| 7. |
Villanueva V, López FJ, Serratosa JM, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav, 2013, 29(2): 349-356.
|
| 8. |
Nakhutina L, Kunnakkat SD, Coleman M, et al. Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy. Epilepsy Behav, 2017, 73: 90-94.
|
| 9. |
Lancman ME, Fertig EJ, Trobliger RW, et al. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy. Epilepsy Behav, 2016, 61: 27-33.
|
| 10. |
Lattanzi S, Cagnetti C, Foschi N, et al. Lacosamide during pregnancy and breastfeeding. Neurol Neurochir Pol, 2017, 51(3): 266-269.
|
| 11. |
Liu Yong, Zhang Hua. Lacosamide combination successfully treated simple partial epilepsy with frequent seizures during pregnancy. Chinese Anti-epilepsy Association. Proceedings of the 8th CAAE International Epilepsy Forum, 2019: 320.
|
| 12. |
Kitamura S, Nishimura A, Takekuma Y, et al. Case report on a woman with epilepsy who took lacosamide during pregnancy and gave birth to a healthy infant. Yakugaku Zasshi, 2022, 142(9): 1031-1035.
|
| 13. |
Hoeltzenbein M, Slimi S, Fietz AK, et al. Increasing use of newer antiseizure medication during pregnancy: an observational study with special focus on lacosamide. Seizure, 2023, 107: 107-113.
|
| 14. |
Scheuerle AE, Holmes LB, Albano JD, et al. Levetiracetam pregnancy registry: final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations. Birth Defects Res, 2019, 111(13): 872-887.
|
| 15. |
Veroniki AA, Rios P, Cogo E, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open, 2017, 20, 7(7): e017248.
|
| 16. |
Mari L, Placidi F, Romigi A, et al. Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy? Neurol Sci, 2022, 43(3): 1993-2001.
|
| 17. |
Athar F, Ehsan M, Farooq M, et al. Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: a systematic review and meta-analysis. Br J Clin Pharmacol, 2022, 88(8): 3600-3609.
|
1/5
WeChat